| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | |||||
| Gross Profit | $ 17.66B | $ 20.85B | $ 13.61B | $ 6.63B | $ 4.07B |
| Operating Income | $ 8.89B | $ 13.66B | $ 6.52B | $ 1.99B | $ -69.00M |
| EBITDA | $ 14.80B | $ 17.66B | $ 9.64B | $ 4.30B | $ 2.43B |
| Net Income | $ 15.00B | $ 12.56B | $ 5.52B | $ 721.00M | $ -862.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― | $ ― | $ ― |
| Total Assets | $ 106.62B | $ 82.34B | $ 62.13B | $ 52.15B | $ 25.72B |
| Total Debt | $ 2.37B | $ 1.50B | $ 8.87B | $ 2.13B | $ 1.78B |
| Net Debt | $ -26.72B | $ -20.68B | $ -8.83B | $ -17.25B | $ -4.48B |
| Total Liabilities | $ 43.01B | $ 36.44B | $ 31.12B | $ 28.47B | $ 26.20B |
| Stockholders' Equity | $ ― | $ ― | $ ― | $ ― | $ ― |
| Cash Flow | |||||
| Free Cash Flow | $ 4.36B | $ 7.57B | $ 5.01B | $ 2.55B | $ 1.07B |
| Operating Cash Flow | $ 13.26B | $ 14.72B | $ 11.50B | $ 5.71B | $ 2.40B |
| Investing Cash Flow | |||||
| Financing Cash Flow |
NurExone Biologic (TSE:NRX)
:NRX
